Poter | Local Directory for Australian Businesses

UB-923 anti-CD20 (Rituxan® )Biobetter

PID: 2074520

Model No:

Made in:

Quantity:

1000 Piece(s)Available

Payment:

Send Inquiry

Supplier Details

UNITED BIOPHARMA, INC.

Member Since

Address

新竹縣湖口鄉光復北路45-1號

+886-03-5973155

Contact Seller

Product Specifications

Type

Antibiotics

Key Features

Mechanism of Action
UB-923 is a biobetter version of rituximab, targeting the CD20 antigen which is mainly expressed on the normal and cancerous B cells. UB-923 is engineered to be afucosylated utilizing our proprietary de-fucosylation technology.
Features
1. UB-923 exhibits a 10-fold higher ADCC activity than Rituxan® and maintains the normal CDC activity.
Potential indication
1. B cell Non-Hodgkin‘s Lymphoma (NHL)
2. Chronic lymphocytic leukemia (CLL)
3. Follicular lymphoma (FL)
Market Opportunity
1. The global sales of Rituxan® was US$7.5B in 2017.
Unmet need
1. New drugs with minimal side effects
2. New drugs for Rituxan®-resistant patients

This is a notification message!